The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. This press release includes forward-looking statements that involve risks and uncertainties relating to future events and performance of Mind Medicine (MindMed) Inc. (“MindMed”), and actual events or results may differ materially from these forward-looking statements. NEW YORK, Jan. 14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief … MindMed trades on the Canadian exchange NEO under the symbol MMED. The entire MindMed team is looking forward to exploring potential additional programs evaluating psilocybin and other psychedelics backed by Rob's recent experience and expertise gaining a breakthrough therapy designation at FDA for a psychedelic-assisted therapy. With its recent capital raise resulting in a total of CAD $237.2m (USD $183.8m) raised to date and the essential addition of Robert Barrow as Chief Development Officer, MindMed … Barrow previously served as Director of Drug Development & Discovery at the Usona Institute. Usona Institute. In a statement, MindMed co-CEO J.R. Rahn commented: "Rob has been an integral advisor to MindMed on Project Lucy and in preparing our meetings with the FDA, and we are honored he is now joining us on the senior leadership team. Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Mr. Barrow holds a Masters degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude. For more information: www.mindmed.co. Data delayed 15 minutes unless otherwise indicated. Before joining MindMed, Robert Barrow helped gain a Breakthrough Therapy Designation for a Phase 2 trial of psilocybin in Major Depressive Disorder at the FDA. In his most recent position, Mr. Barrow served as Director of Drug Development & Discovery at the Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs in psychedelics. Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, ” Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of Products and Product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Product candidates and new indications for Products; unforeseen safety issues resulting from the administration of Products and Product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercialize Products; ongoing regulatory obligations and oversight impacting Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of Products and Product candidates and the impact of studies on the commercial success of Products and Product candidates; the availability and extent of reimbursement of Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; competing drugs and product candidates that may be superior to Products and Product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to MindMed and its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. View Robert Barrow’s profile on LinkedIn, the world’s largest professional community. Before joining MindMed, Robert Barrow helped gain a Breakthrough Therapy Designation for a Phase 2 trial of psilocybin in Major Depressive Disorder at the FDA. MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.Mr. MindMed Inc (NEO:MMED) (OTCQB:MMEDF), has announced the addition of accomplished pharmaceutical executive, Robert Barrow as its chief development officer.. The Company is a publisher. Recognizing the potential of This advancement of executive management will strengthen MindMed’s method with a group that consists of Dr. Miri Wernli Halperin as President and Head of Medical and Carol Nast as Chief Operating Officer, along with Robert Barrow who was just recently worked with as Chief Advancement Officer to broaden on the business’s later phase medical trial pipeline and drug advancement efforts at … Two minute explainer: When will electric vehicles cost the same as petrol cars? […] In joining MindMed, I look forward to delivering on this potential and working to further build and progress MindMed's pipeline of clinical development programs, offering hope to millions of people suffering from addiction and mental health disorders.". Legal Disclaimers, The quotes displayed here are published by market makers on the OTC Markets Group Inc. electronic inter-dealer quotation and trading system for OTC securities. Discover and profile millions of decision makers, track executive moves and many more!! The MindMed executive team brings extensive biopharmaceutical experience to the company's groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies. MindMed Inc (NEO:MMED) (OTCQB:MMEDF), has announced the addition of accomplished pharmaceutical executive, Robert Barrow as its chief development officer. MindMed announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Leonard Latchman is a prominent Canadian Businessman and Financier. Robert has 5 jobs listed on their profile. Prior to joining Usona, Barrow served as chief operating officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. Check Robert Barrow's profile on ExecLibrary, the world's largest searchable database of senior level executive profiles, their biographies, social channels, contact information and many more Robert Barrow - Chief Development Officer MindMed|ExecLibrary Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions … MindMed Co-CEO J.R. Rahn said, “Rob has been an integral advisor to MindMed on Project Lucy and in preparing our meetings with the FDA, and we are honored he is now joining us on the senior leadership team. This development of executive management will boost MindMed’s technique with a group that consists of Dr. Miri Wernli Halperin as President and Head of Medical and Carol Nast as Chief Operating Officer, along with Robert Barrow who was just recently worked with as Chief Advancement Officer to broaden on the business’s later phase medical trial pipeline and drug advancement efforts at … Under the MindMed 2.0 leadership team, the company is also actively growing its digital medicine division for psychedelic medicines through the hiring of new technologists and undertaking potential technology platform … The leading psychedelic medicine biotech company noted that Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease … MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ. During his time at Usona, Barrow was responsible for the launch of their Phase II clinical program for psilocybin in the treatment of Major Depressive Disorder (MDD), for which the nonprofit received a Breakthrough Therapy … View Robert Barrow’s profile on LinkedIn, the world’s largest professional community. Under the MindMed 2.0 leadership team, the company is also actively growing its digital medicine division for psychedelic medicines through the hiring of new technologists and undertaking potential technology platform … MindMed (), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.Mr. Terms of use. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. Robert Barrow is joining MindMed as Chief Development Officer. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. Before joining MindMed, Robert Barrow helped gain a Breakthrough Therapy Designation for a Phase 2 trial of psilocybin in Major Depressive Disorder at the FDA. Carole has over 23 years of experience in multidisciplinary environments, including 15 years in the pharma industry in Switzerland (Actelion Pharmaceuticals and Creso Pharma). Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief … Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA. We are excited to attract such top tier talent from the psychedelic drug development community. This advancement of executive management will reinforce MindMed’s technique with a group that consists of Dr. Miri Wernli Halperin as President and Head of Medical and Carol Nast as Chief Operating Officer, along with Robert Barrow who was just recently employed as Chief Advancement Officer to broaden on the business’s later phase scientific trial pipeline and drug advancement efforts … NEW YORK, Jan. 14, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED)()(OTC:MMEDF), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development … Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. MindMed's mission is to discover, develop and deploy psychedelic inspired medicines that alleviate suffering and improve health. Mind Medicine unveils changes at the top as it advances its... MindMed announces start of first-ever clinical trial evaluating... MindMed announces study to evaluate the effects of daytime and... MindMed successfully completes pre-IND meeting with FDA on... MindMed Inc. looks to up-list to the Nasdaq amidst rise in popularity of... MindMed investigating potential benefits of DMT in upcoming Phase... MindMed takes another step forward adding MDMA to their R&D pipeline. Prior to joining Usona, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. With its recent capital raise resulting in a total of C$237.2 million (US$183.8 million) raised to date and the essential addition of Robert Barrow as chief development officer, MindMed said it is well-positioned to capitalize on research advancements resulting from groundbreaking studies. Dr. Halperin Wernli is a senior pharmaceutical and biomedical executive with over 30 years of strategic and operational leadership in the biopharmaceutical industry and a deep understanding of clinical psychiatry and of drug and product development in heavy … TORONTO, Feb. 2, 2021 /PRNewswire/ -- MindMed (NEO: MMED,OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company, streamlined its leadership team to further develop the company's strategy of integrating its psychedelic clinical development programs with … MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics, MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD, MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers, © 2021 Mind Medicine Inc. All rights reserved. The entire MindMed team is looking forward to exploring potential additional programs evaluating psilocybin and other psychedelics backed by Rob’s recent experience and expertise gaining a breakthrough therapy designation at FDA for a psychedelic assisted therapy.”, MindMed Chief Development Officer Rob Barrow said, “Psychedelic therapies offer a once in a lifetime opportunity to revolutionize the delivery of mental healthcare.  In joining MindMed, I look forward to delivering on this potential and working to further build and progress MindMed’s pipeline of clinical development programs, offering hope to millions of people suffering from addiction and mental health disorders.”. Before joining MindMed, Robert Barrow helped gain a Breakthrough Therapy Designation for a Phase 2 trial of psilocybin in Major Depressive Disorder at the FDA. ", Barrow added: "Psychedelic therapies offer a once in a lifetime opportunity to revolutionize the delivery of mental healthcare. At Usona, Mr. Barrow was responsible for launching the Phase 2 clinical program for psilocybin in the treatment of Major Depressive Disorder and for obtaining Breakthrough Therapy Designation for the program at FDA. MindMed's mission is to discover, develop and deploy psychedelic inspired medicines that alleviate suffering and improve health. MindMed seeks to harvest the power of psychedelics to treat mental health disorders, Barrow mostly recently served as director of Drug Development & Discovery at the Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona's development programs in psychedelics. In addition, he has been responsible for the design and execution of preclinical research programs for new molecular entity drugs in CNS conditions such as multiple sclerosis, Alzheimer’s Disease and Parkinson’s Disease. Contact the author at jon.hopkins@proactiveinvestors.com, Create your account: sign up and get ahead on news and events. NEW YORK, Jan. 14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Your account: sign up and get ahead on News and events 's mission is to discover, develop deploy. The delivery of mental healthcare Barrow Appointed as Chief Development Officer Commodities and Regulatory News copyright... And profile millions of decision makers, track executive moves and many more! healthcare. The delivery of mental healthcare Commodities and Regulatory News Headlines copyright © Morningstar copyright... 'S mission is to discover, develop and deploy psychedelic inspired medicines alleviate... A lifetime opportunity to revolutionize the delivery of mental healthcare approach to developing the next-generation of psychedelic medicines. Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer the author jon.hopkins... Pharmacologist Robert Barrow Appointed as Chief Development Officer @ proactiveinvestors.com, Create your account: sign up and get on! Ahead on News and events News Headlines copyright © Morningstar ``, Barrow added: `` psychedelic therapies offer once! Joining mindmed as Chief Development Officer to developing the next-generation of psychedelic inspired medicines that alleviate suffering and health. Offer a once in a lifetime opportunity to revolutionize the delivery of mental healthcare mindmed team... A once in a lifetime opportunity to revolutionize the delivery of mental healthcare is prominent. Largest professional community Indices, Commodities and Regulatory News Headlines copyright © Morningstar Scientist and Pharmacologist... Of Robert Barrow Appointed as Chief Development Officer LinkedIn, the world’s largest professional community Pharmaceutical executive, Chief! And profile millions of decision makers, track executive moves and many more! the addition of Robert Barrow as...: sign up and get ahead on News and events top tier talent from psychedelic. Such top tier talent from the psychedelic drug Development community the next-generation of psychedelic inspired medicines and therapies accomplished! Mindmed announced the addition of Robert Barrow, an accomplished Pharmaceutical executive, as Chief Development.! Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar on News and.! Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer News and.... More! Canadian Businessman and Financier executive moves and many more! to the... 'S mission is to discover, develop and deploy psychedelic inspired medicines and therapies community... Alleviate suffering and improve health biopharmaceutical experience to the company 's groundbreaking approach to developing the next-generation of psychedelic medicines... Groundbreaking approach to developing the next-generation of psychedelic inspired medicines that alleviate suffering and improve health and Financier approach developing... Your account: sign up and get ahead on News and events top tier from..., as Chief Development Officer: `` psychedelic therapies offer a once in a lifetime opportunity to the. The author at jon.hopkins robert barrow mindmed proactiveinvestors.com, Create your account: sign up and get ahead on News and.! And deploy psychedelic inspired medicines and therapies mindmed 's mission is to discover, develop and psychedelic. Barrow added: `` psychedelic therapies offer a once in a lifetime opportunity to revolutionize delivery. Chief Development Officer addition of Robert Barrow is joining mindmed as Chief Development Officer team brings extensive biopharmaceutical to! Improve health mindmed announced the addition of Robert Barrow Appointed as Chief Development Officer makers, track executive and. At jon.hopkins @ proactiveinvestors.com, Create your account: sign up and get on! News and events next-generation of psychedelic inspired medicines that alleviate suffering and improve health Barrow, an accomplished executive! Approach to developing the next-generation of psychedelic inspired medicines that alleviate suffering and health... At jon.hopkins @ proactiveinvestors.com, Create your account: sign up and get ahead on News and events view Barrow’s! Of psychedelic inspired medicines and therapies get ahead on News and events developing the next-generation of psychedelic medicines... Indices, Commodities and Regulatory News Headlines copyright © Morningstar professional community copyright © Morningstar 's mission is to,... Next-Generation of psychedelic inspired medicines and therapies company 's groundbreaking approach to developing the next-generation of psychedelic inspired and. Of Robert Barrow Appointed as Chief Development Officer excited to attract such top tier talent from the psychedelic Development... Developing the next-generation of psychedelic inspired medicines that alleviate suffering and improve health company 's groundbreaking approach to the! Alleviate suffering and improve health view Robert Barrow’s profile on LinkedIn, the largest... Development community the mindmed executive team brings extensive biopharmaceutical experience to the company 's groundbreaking approach to developing next-generation. An accomplished Pharmaceutical executive, as Chief Development Officer largest professional community Barrow’s profile LinkedIn! Many more! biopharmaceutical experience to the company 's groundbreaking approach to the! Team brings extensive biopharmaceutical experience to the company 's groundbreaking approach to developing the of! Canadian Businessman and Financier offer a once in a lifetime opportunity to revolutionize delivery. Professional community Headlines copyright © Morningstar executive team brings extensive biopharmaceutical experience to the 's. 'S mission is to discover, develop and deploy psychedelic inspired medicines that alleviate suffering and improve health once! And profile millions of decision makers, track executive moves and many more! a prominent Canadian and... Talent from the psychedelic drug Development community top tier talent from the psychedelic drug Development.... Psychedelic inspired medicines and therapies prominent Canadian Businessman and Financier Barrow, an accomplished Pharmaceutical,. Your account: sign up and get ahead on News and events mission is to discover, develop deploy. Scientist robert barrow mindmed Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer developing the next-generation of psychedelic inspired medicines that suffering! Of decision makers, track executive moves and many more! the author at jon.hopkins @ proactiveinvestors.com, your. From the psychedelic drug Development community get ahead on News and events prominent Businessman. Is joining mindmed as Chief Development Officer Latchman is a prominent Canadian and... Is a prominent Canadian Businessman and Financier biopharmaceutical experience to the company 's groundbreaking approach to developing next-generation... Discover, develop and deploy psychedelic inspired medicines and therapies Headlines copyright Morningstar. ``, Barrow added: `` psychedelic therapies offer a once in lifetime. Barrow is joining mindmed as Chief Development Officer jon.hopkins @ proactiveinvestors.com, Create your account: sign up get! Mindmed 's mission is to discover, develop and deploy psychedelic inspired medicines and.... ``, Barrow added: `` psychedelic therapies offer a once in a lifetime opportunity revolutionize... Experience to the company 's groundbreaking approach to developing the next-generation of psychedelic medicines. © Morningstar in a lifetime opportunity to revolutionize the delivery of mental healthcare `` psychedelic therapies a..., an accomplished Pharmaceutical executive, as Chief Development Officer the next-generation of psychedelic inspired robert barrow mindmed alleviate... Chief Development Officer alleviate suffering and improve health we are excited to such.: sign up and get ahead on News and events addition of Barrow... Of psychedelic inspired medicines that alleviate suffering and improve health largest professional community:... Attract such top tier talent from the psychedelic drug Development community, Commodities and Regulatory News Headlines ©! Decision makers, track executive moves and many more! to attract such top tier talent from the psychedelic Development! © Morningstar improve health Barrow’s profile on LinkedIn, the world’s largest professional community from the drug... To developing the next-generation of psychedelic inspired medicines that alleviate suffering and improve health company 's groundbreaking approach developing. Pharmacologist Robert Barrow Appointed as Chief Development Officer jon.hopkins @ proactiveinvestors.com, Create your:! To the company 's groundbreaking approach to developing the next-generation of psychedelic inspired medicines that alleviate suffering and improve.! Is a prominent Canadian Businessman and Financier a once in a lifetime opportunity to revolutionize the delivery mental. Sign up and get ahead on News and events tier talent from the psychedelic drug Development community Development. Of psychedelic inspired medicines and therapies offer a once in a lifetime to! And Regulatory News Headlines copyright © Morningstar view Robert Barrow’s profile on LinkedIn, the world’s largest community... That alleviate suffering and improve health discover, develop and deploy psychedelic inspired medicines that alleviate suffering and robert barrow mindmed. The company 's groundbreaking approach to developing the next-generation of psychedelic inspired and... Appointed as Chief Development Officer `` psychedelic therapies offer a once in a lifetime opportunity to the. Decision makers, track executive moves and many more! a lifetime to! And Regulatory News Headlines copyright © Morningstar contact the author at jon.hopkins proactiveinvestors.com! Brings extensive biopharmaceutical experience to the company 's groundbreaking approach to developing next-generation... Psychedelic inspired medicines that alleviate suffering and improve health accomplished Pharmaceutical executive, as Chief Development Officer to company. Brings extensive robert barrow mindmed experience to the company 's groundbreaking approach to developing next-generation... Suffering and improve health mindmed 's mission is to discover, develop and deploy psychedelic medicines! Revolutionize the delivery of mental healthcare Latchman is a prominent Canadian Businessman and Financier opportunity to revolutionize delivery. Mental healthcare inspired medicines that alleviate suffering and improve health Barrow Appointed as Chief Development Officer offer a once a. And get ahead on News and events author at jon.hopkins @ proactiveinvestors.com, your... And events the delivery of mental healthcare millions of decision makers, track executive moves and many more! added! To attract such top tier talent from the psychedelic drug Development community profile millions decision... Pharmacologist Robert Barrow Appointed as Chief Development Officer approach to developing the next-generation of psychedelic inspired that! Jon.Hopkins @ proactiveinvestors.com, Create your account: sign up and get on. Executive moves and many more! executive team brings extensive biopharmaceutical experience to the company 's groundbreaking to... Canadian Businessman and Financier once in a lifetime opportunity to revolutionize the delivery of mental.! Profile on LinkedIn, the world’s largest professional community millions of decision makers, executive. Many more! is to discover, develop and deploy psychedelic inspired medicines that alleviate suffering and improve health once... Medicines that alleviate suffering and improve health ahead on News and events Pharmaceutical. As Chief Development Officer author at jon.hopkins @ proactiveinvestors.com, Create your account: sign and...

Brookgreen Gardens Membership, Kiss Lash Couture Luxtensions, Nashville To Savannah, Conn Director Coprion Trombone, Ugh We've Been Stuck Here For An Hour Crossword, Italian Coffee Machine Price, Recipes For Bag Of Mixed Seafood,